(Q53944149)

22 May 2018

title

Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. (English)

1 reference

22 May 2018

0 references

0 references

R R Conley

1

1 reference

22 May 2018

D L Kelly

series ordinal

2

1 reference

22 May 2018

E A Gale

series ordinal

3

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 September 1998

1 reference

22 May 2018

published in

Schizophrenia Research

1 reference

22 May 2018

volume

33

1 reference

22 May 2018

issue

1-2

1 reference

22 May 2018

page(s)

95-101

1 reference

22 May 2018

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Psychotogenic drug use and neuroleptic response

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Cocaine abuse among schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Hallucinogenic drugs as precipitants of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Alcohol use and abuse in schizophrenia. A prospective community study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Relapse in schizophrenia: is there a relationship to substance abuse?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

Past substance abuse and clinical course of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2898%2900062-0

7 January 2021

10.1016/S0920-9964(98)00062-0

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018